• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

31.12 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
January 11, 2026
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
December 06, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
November 12, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
November 04, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
August 25, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
August 14, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
August 05, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
June 13, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
June 03, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 29, 2025
From Beam Therapeutics
Via GlobeNewswire
BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025
May 23, 2025
Via Investor Brand Network
News headline image
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
May 14, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
May 13, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 12, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 06, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
April 05, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
March 27, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Pricing of Underwritten Offering
March 10, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
March 10, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
February 25, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
February 24, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
January 30, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
January 23, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
January 13, 2025
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
December 08, 2024
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
December 07, 2024
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
December 06, 2024
From Beam Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap